Mukadder ÇALIKOĞLU, Ali ÜNLÜ, Eylem ÖZGÜR, Lülüfer TAMER

5162

Kronik obstrüktif akciğer hastaları ve astımlılarda indükte balgamda MMP-9 ve TIMP-1 düzeyleri

Kronik obstrüktif akciğer hastalığı (KOAH) ve astım, hava yolları ve akciğerde yapısal değişikliklerle seyreden hastalıklar olup, bu süreçte metalloproteinazların rol oynadığı düşünülmektedir. Çalışmamızın amacı; stabil dönemdeki KOAH ve astımlı hastaların hava yollarındaki matriks metalloproteinaz-9 (MMP-9) ve matriks metalloproteinaz doku inhibitörü (TIMP)-1’in düzeylerini belirlemek ve sağlıklılarla karşılaştırmaktır. Yirmiiki stabil KOAH, 20 stabil astımlı hasta ve 15 sağlıklı kontrolün indükte balgamında MMP-9 ve TIMP-1 düzeyleri ELISA ticari kitleri kullanılarak ölçüldü. MMP-9 ve TIMP-1 düzeyleri hasta gruplarında sağlıklı kontrollere göre yüksekti. KOAH hastalarında MMP-9 ve TIMP-1 kontrol grubundan anlamlı yüksekti (sırayla; p= 0.0001, p= 0.0001). Benzer şekilde astım hastalarında MMP-9 ve TIMP-1 düzeyleri de kontrol grubundan daha yüksekti (sırayla; p= 0.005, p= 0.002). Ancak MMP-9 düzeyleri hasta grupları arasında anlamlı farklılık göstermezken (p= 0.29), TIMP-1 düzeyleri KOAH’lı hastalarda belirgin yüksekti (sırayla; 96.2 ± 58.2, 52.8 ± 52 µg/mg protein, p= 0.0001). Atopik astım hastalarında TIMP-1 düzeyleri nonatopik astımlılara göre anlamlı olmamakla beraber hafifçe yüksekti (p> 0.05). Tüm gruplarda solunum fonksiyon testleri ile TIMP-1 düzeyleri arasında anlamlı bir korelasyon yokken, KOAH’lılarda FEV1 L, astımlılarda da FVC % değerleri arasında korelasyon bulundu. Bilinen patogenetik farklılıklara rağmen, proteaz-antiproteaz düzeylerinde her iki hasta grubunda da izlenen bu artış bronşiyal ve parankimal düzeyde oluşan yapısal değişikliklerle ilişkili olabilir ve artmış proteaz/antiproteaz düzeylerini düzenlemeyi hedefleyen yeni tedavi stratejileri KOAH ve bazı astım hastaları için umut verici olabilir.

MMP-9 and TIMP-1 levels in the sputum of patients with chronic obstructive pulmonary disease and asthma

Chronic obstructive pulmonary disease (COPD) and asthma are associated with morphological changes in airway and lung and metalloproteinases are tought to play a role in this destruction. The aim of this study is to compare the levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinases (TIMP)-1 in the airways of COPD and asthma patients in stable period. We measured MMP-9 and TIMP-1 levels in the induced sputum of 20 asthma, 22 COPD patients in stable period and 15 healthy controls. MMP-9 and TIMP-1 levels were measured by using ELISA kits. MMP-9 and TIMP-1 levels were higher in patient groups than the controls. In COPD patients MMP-9 and TIMP-1 were significantly higher than the controls (respectively; p= 0.0001, p= 0.0001). Similarly, in asthma patients MMP-9 and TIMP-1 levels were higher than the controls (respectively; p= 0.005, p= 0.002). However, while there were no significant difference in MMP-9 levels between the patient groups (p= 0.29), TIMP-1 levels were significantly higher in COPD patients (96.2 ± 58.2 versus 52.8 ± 52 µg/mg protein, respectively, p= 0.0001). Atopic asthma patients TIMP-1 levels were slightly higher than non-atopic asthma patients (p> 0.05). There was no significant correlation between FEV1 and MMP-9 or TIMP-1 levels in all groups. Although known pathogenetic differences in COPD and asthma, the increases in protease-antiprotease levels in both two patient groups may be associated with bronchial and parenchimal morphological changes. New treatment strategies which are focused on modulating of increased protease-antiprotease levels may be give a hope to patients with COPD and asthma.
PDF

___

  • 1. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: Comparisons with asthma. J Allergy Clin Immunol 2003; 112: 819-27.
  • 2. Repine JE, Bast A, Lankhorst I. The Oxidative Stres Study Group. Oxidative stres in chronic obstructive pulmonary disease. Am J Crit Care Med 1997; 156: 341-57.
  • 3. Hargreave FE, Gibson GP. Evidence from induced sputum. In: Holgate ST, William WB (eds). Inflammatory Mechanisms in Asthma. New York: Basel, 1998: 75-88.
  • 4. Demedts IK, Brusselle GG, Bracke KR, et al. Matrix metalloproteinases in asthma and COPD. Curr Opin Pharmacol 2005; 5: 257-63.
  • 5. Culpitt SV, Rogers DF, Traves SL, et al. Sputum matrix metalloproteases: Comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005; 99: 703-10.
  • 6. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002; 3: 409-21.
  • 7. Kelly EA, Jarjour NN. Role of matrix metalloproteinases in asthma. Curr Opin Pulm Med 2003; 9: 28-33.
  • 8. Delcaux C, Delacourt C, d’Ortho M, et al. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol 1996; 14: 288-94.
  • 9. Buhl R, Meyer A, Vogelmeier C. Oxidant-protease interaction in the lung. Chest 1996; 110: 267-72.
  • 10. Dunsmore SE, Saarialho-Kere UK, Roby JD, et al. Matrilysin expression and function in airway epithelium. J Clin Invest 1998; 102: 1321-31.
  • 11. Triebel S, Blaser J, Gote T, et al. Evidence for the tissue inhibitor of metalloproteinases-1 (TIMP-1) in human polymorphonuclear leukocytes. Eur J Biochem 1995; 231: 714-9.
  • 12. Labierte R, Rpuabhia M, Bosse M, and Chakir J. Decreased capacity of asthmatic bronchial fibroblasts to degrade collogen. Matrix Biology 2001; 19: 743-53
  • 13. Prikk K, Maisi P, Pirila E, et al. Airway obstruction correlates with collagenase-2 (MMP-8) expression and activation in bronchial asthma. Lab Invest 2002; 82: 1535-45.
  • 14. Tanaka H, Miyazaki N, Oashi K, et al. Sputum matrix metalloproteinase- 9: Tissue inhibitor of metalloproteinase-1 ratio in acute asthma.J Allergy Clin Immunol 2000; 105:900-5.
  • 15. Global Strategy for Diagnosis, Management and Prevention of COPD. NHLBI/ WHO Workshop Report: Bethesda, National Heart, Lung and Blood Institute. Apr 2001; NIH Publication No: 2701: 1-100. Updated of the Management Sections, GOLD Website. Updated 2003.
  • 16. National Institutes of Health. National Heart, Lung, and Blood Institute. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report: 2002.
  • 17. Nagata M. Inflammatory cells and oxygen radicals. Curr Drug Targets Inflamm Allergy 2005; 4: 503-4.
  • 18. Türktaş H, Kalyoncu F, Gemicioğlu B ve ark. Astımda tanıya yönelik pratik uygulama kılavuzu. Toraks Dergisi 2003; 4 (Ek).
  • 19. Higashimoto Y, Yamagata Y, Iwata T, et al. Increased serum concentrations of tissue inhibitor of metalloproteinase- 1 in COPD patients. Eur Respir J 2005; 25: 885-90.
  • 20. Shapiro SD. Elastolytic metalloproteinases produced by human mononuclear phagocytes: Potential roles in destructive lung disease. Am J Respir Crit Care Med 1994; 150: 160-64.
  • 21. Janoff A, Raju L, Dearing R. Levels of elastase activity in bronchoalveolar lavage fluids of healthy smokers and nonsmokers. Am Rev Respir Dis 1983; 127: 540-44.
  • 22. Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL- 13 to the lung cause matrix metalloproteinase-and catepsin –dependent emphysema. J Clin Invest 2000; 106: 1081-93.
  • 23. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 50-60.
  • 24. Calikoglu M, Unlu A, Tamer L, et al. The levels of serum vitamin C, malonyldialdehyde and erythrocyte reduced glutathione in chronic obstructive pulmonary disease and in healthy smokers. Clin Chem Lab Med 2002; 40: 1028-31.
  • 25. Cataldo D, Munaut C, Noel A, et al. Matrix metalloproteinases and TIMP-1 production by peripheral blood granulocytes from COPD patients and asthmatics. Allergy 2001; 56: 145-51.
  • 26. Cataldo D, Munaut C, Noel A, et al. MMP-2- and MMP-9- linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000; 123: 259-67.
  • 27. Lechapt-Zalcman E, Escudier E. Implication of extracellular matrix metalloproteinases the course of chronic inflamatory airway diseases. Morpholgie 2000; 84: 45-9.
  • 28. Ohbayashi H, Shimokata K. Matrix metalloproteinase-9 and airway remodeling in asthma. Curr Drug Targets Inflamm Allergy 2005; 4: 177-81.
  • 29. Lemjbbar H, Gosset P, Lamblin C, et al. Contribution of 92 kDa gelatinase type 4 collagenase in bronchial inflammation during status asthmaticus. Am Respir Crit Care Med 1999; 159: 1298-307.
  • 30. Lamblin C, Gosset P, Leblond I, et al. Bronchial neutrophilia in patients with noninfectious status astmaticus. Am J Respir Crit Care Med 1998; 157: 394-402.
  • 31. Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160: 1532-39.
  • 32. Kumagai K, Onho I, Okado S, et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. The Journal of Immunology 1999; 162: 4212-19.
  • 33. Onho I, Ohtani H, Nitta Y, et al. Eosinophil as source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1997; 16: 212-15.
  • 34. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase- 9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158: 1945-50.
  • 35. Ko FW, Diba C, Roth M, et al. A comparison of airway and serum matrix metalloproteinase-9 activity among normal subjects, asthmatic patients, and patients with asthmatic mucus hypersecretion. Chest 2005; 127: 1919-27.
Tüberküloz ve Toraks-Cover
  • ISSN: 0494-1373
  • Yayın Aralığı: 4
  • Başlangıç: 1951
  • Yayıncı: Tuba Yıldırım
Arşiv
Sayıdaki Diğer Makaleler

Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?

Gizem DEMİR, Eriş Banu GÜLBAY, Zeynep Pınar ÖNEN, Gülseren KARABIYIKOĞLU, Sevgi SARYAL, Akkoca Öznur YILDIZ

İleri evre küçük hücreli dışı akciğer karsinomunda sisplatin-etoposid ile mitomisin-ifosfamid-sisplatin kombinasyonlarının karşılaştırılması

Hülya ATIL, Asuman GÜZELANT, Gürsel ÇOK, Serdar SOYER, Tülin AYSAN, Tuncay GÖKSEL

Primer pulmoner lenfoma

Sibel ARINÇ, Adnan YILMAZ

Effects of N-acetylcysteine on the lung histopathology and oxidant-antioxidant status in rabbits exposed to cigarette smoke

Tülay KÖKEN, Önder ŞAHİN, Mehmet ÜNLÜ, Murat SEZER, Hıdır ESME, Fatma FİDAN

Clinical effectiveness of nebulised budesonide in the treatment of acute asthma attacks

Dane EDİGER, Ercüment EGE, Gürdal Eser YÜKSEL, Kunt Esra UZASLAN, Funda COŞKUN, Oktay GÖZÜ, Mehmet KARADAĞ

Kronik obstrüktif akciğer hastaları ve astımlılarda indükte balgamda MMP-9 ve TIMP-1 düzeyleri

Mukadder ÇALIKOĞLU, Ali ÜNLÜ, Eylem ÖZGÜR, Lülüfer TAMER

Timik kistler: Altı olgu nedeniyle

Sibel ARINÇ, Ali ATASALİHİ, Ebru SULU, Müyesser ERTUĞRUL, Ebru DAMADOĞLU, Yağcı Leyla TUNCER, Bayram Ümmühan SELVİ, Adnan YILMAZ

A Behçet’s disease patient with intracardiac thrombus, pulmonary artery aneurysms complicating recurrent pulmonary thromboembolism

Figen ATALAY, Dilek ERNAM, Aysun ALP, H. Canan HASANOĞLU

Inhaled iloprost as a long-term additional therapy to oral sildenafil in severe idiopathic pulmonary arterial hypertension

Eriş Banu GÜLBAY, Zeynep Pınar ÖNEN, Gülseren KARABIYIKOĞLU, Akkoca Öznur YILDIZ

An unusual reason of parotid gland enlargement; parotid gland tuberculosis

Ümit ÇAKIR, Balaban Şaduman ADIM, Esra UZASLAN, Ezgi DEMİRDÖĞEN, Arzu SALAN, Beril ERDOĞAN